No doubt those attending have plenty on their minds to ask during Q&A already. 

However, in case anyone is willing, i have a couple questions i would love to add to the stack if they don't mention in their presentation.

1. When and if development of any other compounds is intended, and have any realistic compunds been identified /are any shareable yet. (i.e. what's up with the pipeline)

2. Financing for additional compounds available or company survival actually dependent purely on Apabetalone? Marketing and operational plans?

3. I really want to know whether they are looking at any other inflammation indications. Understand that the nephrologists are all excited, but would love them to also look at some that may include but need not be kidney/diabetes specific. Anemia of chronic disease (now aka anemia of chronic inflammation) can be caused by diabetes, but also by pressure sores, cancers, and other issues. The market is not as large as Cardio, Alzheimers, or Diabetes, but it is still relatively large (second most prevalent type of anemia) and growing/expected to grow, with large unmet need. Current solutions are limited and not fully effective, or have potential adverse effects. Novel solutions under investigation include some that block IL-6 and hepcidin. Seems like a natural market to consider adding, and would love to see both some post-hoc analysis if possible and/or addition of subgroups to future studies. Would love to see them include both diabetic and non-diabetic inflammation sub groups as the latter cohort really gets left behind in treatment.

If this is something you would considet asking, please feel free to ask for clarification as i am not always able to articulate well at first